Exelixis, Inc. (EXEL)
NASDAQ: EXEL · Real-Time Price · USD
36.20
-0.35 (-0.96%)
At close: Jan 17, 2025, 4:00 PM
36.36
+0.16 (0.44%)
After-hours: Jan 17, 2025, 7:58 PM EST
Exelixis Employees
Exelixis had 1,310 employees as of December 31, 2023. The number of employees increased by 87 or 7.11% compared to the previous year.
Employees
1,310
Change (1Y)
87
Growth (1Y)
7.11%
Revenue / Employee
$1,589,006
Profits / Employee
$356,431
Market Cap
10.34B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1,310 | 87 | 7.11% |
Dec 31, 2022 | 1,223 | 269 | 28.20% |
Dec 31, 2021 | 954 | 181 | 23.42% |
Dec 31, 2020 | 773 | 156 | 25.28% |
Dec 31, 2019 | 617 | 133 | 27.48% |
Dec 31, 2018 | 484 | 112 | 30.11% |
Dec 31, 2017 | 372 | 85 | 29.62% |
Dec 31, 2016 | 287 | 172 | 149.57% |
Dec 31, 2015 | 115 | 17 | 17.35% |
Dec 31, 2014 | 98 | -129 | -56.83% |
Dec 31, 2013 | 227 | 53 | 30.46% |
Dec 31, 2012 | 174 | -26 | -13.00% |
Dec 31, 2011 | 200 | -183 | -47.78% |
Dec 31, 2010 | 383 | -293 | -43.34% |
Dec 31, 2009 | 676 | 0 | - |
Dec 31, 2008 | 676 | -59 | -8.03% |
Dec 31, 2007 | 735 | 84 | 12.90% |
Dec 31, 2006 | 651 | 101 | 18.36% |
Dec 31, 2005 | 550 | 33 | 6.38% |
Dec 31, 2004 | 517 | -56 | -9.77% |
Dec 31, 2003 | 573 | 23 | 4.18% |
Dec 31, 2002 | 550 | -21 | -3.68% |
Dec 31, 2001 | 571 | 214 | 59.94% |
Dec 31, 2000 | 357 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
EXEL News
- 8 days ago - Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025 - Business Wire
- 10 days ago - The Best Defensive Stocks To Hedge Against Market Uncertainty - Seeking Alpha
- 11 days ago - Exelixis: Bullish On Cabo, Not So Convinced By It's Long-Term Replacement, Zanza - Seeking Alpha
- 11 days ago - Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors - Business Wire
- 14 days ago - Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 - Business Wire
- 7 weeks ago - Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December - Business Wire
- 7 weeks ago - Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors - Business Wire
- 2 months ago - Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November - Business Wire